Compare TransMedics Group Inc (TMDX) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Valero Energy Corporation — how do they compare? TransMedics Group Inc trades at $87.28 (market cap $3.10B), while Valero Energy Corporation trades at $329.56 (market cap $93.27B). The key difference: Valero Energy Corporation is far larger — about 30.1× TransMedics Group Inc's market cap, and Valero Energy Corporation pays a 1.48% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | VLO | |
|---|---|---|
Market Cap | $3.10B | $93.27B |
Sector | Technology | Energy |
52-Week High | $150.42 | $323.92 |
52-Week Low | $61.99 | $133.38 |
Enterprise Value | $3.49B | $96.74B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Valero Energy (VLO) trades at $328.43, up 4.28% today, showing strong momentum after recent earnings beats. The stock maintains bullish technical signals with key resistance at $329 and support at $319. Recent Q2 2026 results significantly exceeded expectations with EPS of $12.54 versus $10.11 estimates, driven by robust refining margins and renewable diesel performance. Revenue trends show recovery from 2025's $122.7B to projected $139.4B in 2026.
VLO presents a compelling value opportunity with attractive valuation metrics (P/E 13.51, P/S 0.7) and strong profitability (ROE 29.31%). Analyst consensus favors Buy ratings (55.55%) with $324.27 price target. Key risks include refining margin volatility and geopolitical impacts on oil markets. The company's disciplined capital allocation and dividend payments ($1.20 quarterly) provide shareholder returns amid energy sector transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
